Abstract
Recently, a new view into the molecular mechanisms of phosphate homeostasis and secondary hyperparathyroidism pathogenesis has been proposed, with Fibroblast Growth Factor 23 (FGF-23) as a novel player in the field. Enhanced serum FGF-23 levels cause a reduction in serum phosphate, together with calcitriol suppression and consequent hyperparathyroidism. In contrast, reduced serum FGF-23 levels are associated with hyperphosphatemia, higher calcitriol levels and parathyroid hormone (PTH) suppression. In addition, there are different FGF-23 actions that need investigation. In clinical practice, increased knowledge of mineral metabolism disorders alterations in chronic kidney disease (CKD) may be used to improve diagnostics and select future treatments. The discovery of FGF23 represents a novel factor in the pathogenesis of phosphate handling and secondary hyperparathyroidism in cardiovascular, bone and renal disease.
Keywords: FGF-23, chronic kidney disease, secondary hyperparathyroidism, phosphatonins, vascular calcification, klotho
Current Vascular Pharmacology
Title: The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease
Volume: 8 Issue: 3
Author(s): Mario Cozzolino and Sandro Mazzaferro
Affiliation:
Keywords: FGF-23, chronic kidney disease, secondary hyperparathyroidism, phosphatonins, vascular calcification, klotho
Abstract: Recently, a new view into the molecular mechanisms of phosphate homeostasis and secondary hyperparathyroidism pathogenesis has been proposed, with Fibroblast Growth Factor 23 (FGF-23) as a novel player in the field. Enhanced serum FGF-23 levels cause a reduction in serum phosphate, together with calcitriol suppression and consequent hyperparathyroidism. In contrast, reduced serum FGF-23 levels are associated with hyperphosphatemia, higher calcitriol levels and parathyroid hormone (PTH) suppression. In addition, there are different FGF-23 actions that need investigation. In clinical practice, increased knowledge of mineral metabolism disorders alterations in chronic kidney disease (CKD) may be used to improve diagnostics and select future treatments. The discovery of FGF23 represents a novel factor in the pathogenesis of phosphate handling and secondary hyperparathyroidism in cardiovascular, bone and renal disease.
Export Options
About this article
Cite this article as:
Cozzolino Mario and Mazzaferro Sandro, The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112313
DOI https://dx.doi.org/10.2174/157016110791112313 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress in Essential Hypertension
Current Pharmaceutical Design Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases
Current Protein & Peptide Science Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews Cardioprotective Peptides from Marine Sources
Current Protein & Peptide Science Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Methods to Study Postprandial Lipemia
Current Vascular Pharmacology Homeobox Genes and Human Genetic Disorders
Current Molecular Medicine Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Obesity, Metabolic Syndrome, Diabetes and Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Routine use of Corticosteroids to Prevent Inflammation Response in Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy Role of PI3 Kinase Gamma in Excitation-Contraction Coupling and Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry Adverse Effects of Cigarette Smoke and Induction of Oxidative Stress in Cardiomyocytes and Vascular Endothelium
Current Pharmaceutical Design Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Stacking Regression Algorithms to Predict PM<sub>2.5</sub> in the Smart City Using Internet of Things
Recent Advances in Computer Science and Communications Role of miRNAs in Coronary Artery Disease
Current Signal Transduction Therapy The Potential Role of Statins in Pneumonia
Current Respiratory Medicine Reviews